Literature DB >> 20397916

CT and MRI of hepatocellular carcinoma: an update.

Anoop P Ayyappan1, Kartik S Jhaveri.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and one of the few malignancies with an increasing incidence in the USA. Imaging plays a crucial role in early detection, accurate staging and planning management strategies. Contrast material-enhanced MRI or computed tomography (CT) are the best imaging techniques currently available for the noninvasive diagnosis of HCC. The diagnosis of HCC is strongly dependent on hemodynamic features (arterial hypervascularity and washout in the venous phase) on dynamic imaging, and biopsy is no longer recommended for tumors with classical imaging features prior to treatment. The major challenge for radiologists in imaging cirrhosis is the characterization of hypervascular nodules smaller than 2 cm, which often have nonspecific imaging characteristics. In this review, we discuss the role of CT and MRI in the diagnosis and staging of HCC. The strengths and current limitations of these imaging modalities are highlighted.

Entities:  

Mesh:

Year:  2010        PMID: 20397916     DOI: 10.1586/era.10.24

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  12 in total

Review 1.  Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome.

Authors:  Gar-Yang Chau
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

2.  Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.

Authors:  Jonathan G Sham; Forrest M Kievit; John R Grierson; Peter A Chiarelli; Robert S Miyaoka; Miqin Zhang; Raymond S Yeung; Satoshi Minoshima; James O Park
Journal:  J Nucl Med       Date:  2014-10-30       Impact factor: 10.057

3.  Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles.

Authors:  James O Park; Zachary Stephen; Conroy Sun; Omid Veiseh; Forrest M Kievit; Chen Fang; Matthew Leung; Hyejung Mok; Miqin Zhang
Journal:  Mol Imaging       Date:  2011-02       Impact factor: 4.488

4.  The Presence of Portal Vein Thrombosis Alters the Classic Enhancement Associated with Diagnosis of Hepatocellular Carcinoma.

Authors:  Nadia K Umar; Maaz B Badshah; Kumar Sandrasegaran; Marwan Ghabril; Saurabh Agarwal; Mark Tann; Marco Lacerda; Paul Y Kwo
Journal:  Dig Dis Sci       Date:  2015-03-17       Impact factor: 3.199

Review 5.  MRI of hepatocellular carcinoma: an update of current practices.

Authors:  Hina Arif-Tiwari; Bobby Kalb; Surya Chundru; Puneet Sharma; James Costello; Rainner W Guessner; Diego R Martin
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

6.  Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.

Authors:  Jonathan G Sham; Forrest M Kievit; John R Grierson; Robert S Miyaoka; Matthew M Yeh; Miqin Zhang; Raymond S Yeung; Satoshi Minoshima; James O Park
Journal:  J Nucl Med       Date:  2014-03-13       Impact factor: 10.057

7.  Comparison of usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B endemic area.

Authors:  So Young Bae; Moon Seok Choi; Geum-Youn Gwak; Yong Han Paik; Joon Hyoek Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  Clin Mol Hepatol       Date:  2012-06-26

Review 8.  Pathology-MRI Correlation of Hepatocarcinogenesis: Recent Update.

Authors:  Jimi Huh; Kyung Won Kim; Jihun Kim; Eunsil Yu
Journal:  J Pathol Transl Med       Date:  2015-05-15

Review 9.  The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections.

Authors:  Wasim Abbas; Amit Kumar; Georges Herbein
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

10.  Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts.

Authors:  Z-Y Chen; W Wei; Z-X Guo; L-X Peng; M Shi; S-H Li; C-Z Xiao; C Zhong; C-N Qian; R-P Guo
Journal:  Br J Cancer       Date:  2013-12-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.